Biosimilar Development News

  1. Pharmacy Times Continuing Education Presents The American Journal Of Managed Care (AJMC®) Payer And Specialty Pharmacy Forum: Improving The Adoption Of Oncology Biosimilars In Practice
    6/25/2019

    Pharmacy Times Continuing Education (PTCE), a leader in continuing education for retail, health-system, managed care, and specialty pharmacists, launches The American Journal of Managed Care (AJMC) Payer and Specialty Pharmacy Forum: Improving the Adoption of Oncology Biosimilars in Practice.

  2. European Medicines Agency Accepted First ‘China-Developed’ Biosimilar - Henlius HLX02 Marketing Authorization Application For Review
    6/21/2019

    Henlius, a leading biotech company in China developing both biosimilar and innovative biologics, announced today that the European Medicines Agency (EMA) has officially accepted to review the Marketing Authorization Application (MAA) of its trastuzumab biosimilar HLX02.

  3. Health Experts Agree Increasing Biosimilar Use Can Help Reduce Rising Drug Costs For Patients
    6/20/2019

    Yesterday, notable health leaders spoke about the importance of increasing biosimilars to lower health care costs during a POLITICO panel event sponsored by the Biosimilars Forum. Panelists included Congresswoman Diana DeGette (D-CO), Health and Human Services (HHS) official John O’Brien, University of Pittsburgh Professor Inmaculada Hernández, an expert in pharmacy and therapeutics policy, and Leslie Ritter of the National MS Society.

  4. Vizient To Collaborate With Civica Rx To Help Improve Drug Availability And Affordability By Providing Analytic Data Into Provider Needs
    6/17/2019

    Vizient announces that it is collaborating with Civica Rx to help reduce the impact of drug shortages. By providing insights into purchasing patterns and provider needs through its industry-leading analytics and data capabilities, Vizient will help Civica anticipate gaps in drug availability and affordability.

  5. New Sandoz Biosimilar Adalimumab Data Confirms Switching From Reference Biologic Has No Impact On Safety Or Efficacy
    6/14/2019

    Sandoz, a Novartis division and a global leader in biosimilars, recently announced data from the Phase III ADMYRA trial demonstrating that the efficacy and safety of biosimilar Hyrimoz (adalimumab) matches that of the reference medicine adalimumab with no clinically meaningful differences in patients with moderate-to-severe rheumatoid arthritis (RA) with inadequate response to disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX).

  6. FDA Approves Amgen And Allergan's KANJINTI™ (Trastuzumab-anns), A Biosimilar To Herceptin® (Trastuzumab)
    6/14/2019

    Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

  7. Psoriasis Treatment Market To Gain US$12.1B; Introduction Of Biosimilars To Accelerate Industry Growth, Says TMR
    6/12/2019

    As reported by TMR, the global psoriasis treatment market is prognosticated to exhibit a 5.10% CAGR over the forecast period from 2016 to 2024. The market was estimated to be worth US$7.8 bn in 2015 and is forecasted to reach US$12.1 bn by 2024.

  8. Advisory Council On The Implementation Of National Pharmacare Highlights Importance Of Biosimilar Medicines
    6/12/2019

    The Advisory Council on the Implementation of National Pharmacare’s Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.

  9. Advisory Panel On The Implementation Of National Pharmacare Highlights Importance Of Biosimilar Medicines
    6/12/2019

    The Advisory Council on the Implementation of National Pharmacare's Final Report highlights the importance of biosimilar medicines in the sustainable implementation of a national pharmacare program.1

  10. New Subcutaneous Formulation Of Celltrion Healthcare’s CT-P13 (Biosimilar Infliximab) Shows Positive Results For The Treatment Of Rheumatoid Arthritis (RA) In Data Presented At The Annual European Congress Of Rheumatology (EULAR 2019)
    6/11/2019

    Celltrion Healthcare recently presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with RA during the treatment period of one year.